Dr.Reddys launches osteoporosis generic

DRL has launched the generic version of Reclast in the US market, following USFDA approva


Dr. Reddy's Laboratories announced today that it has launched Zoledronic Acid Injection , a therapeutic equivalent generic version of Reclast (zoledronic acid) injection in the US market. This was following approval by the United States Food and Drug Administration (USFDA) of Dr. Reddy's ANDA for Zoledronic Acid Injection (5 mg/100 mL).

The Reclast brand had total U.S. sales of approximately $355 million for the most recent twelve months ending February 2013 according to IMS Health.Reclast is indicated for treatment of osteoporosis in post
menopausal women. In postmenopausal women with osteoporosis,
diagnosed by bone mineral density (BMD) or prevalent vertebral fracture, Reclast reduces the incidence of fractures (hip,vertebral and non-vertebral osteoporosis-related fractures)

Dr. Reddy's Zoledronic Acid Injection (5 mg/100 mL) is available in a single use vial for Intravenous Infusion.

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email